Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nanobiotix S.A.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nanobiotix S.A.'s regulatory disclosures and financial reporting.
Nanobiotix S.A. reported interim results showing Total Revenue of €24.9 million for the six months ended June 30, 2025, driven primarily by a one‑off €21.2 million cumulative catch‑up from a contract modification with Janssen that increased the constrained transaction price. The company recorded a net loss of €5.4 million for the period and held €28.8 million of cash and equivalents as of June 30, 2025. Management estimates current resources finance operations into mid‑2026 and states additional liquidity of €8–10 million will be required over the next 12 months, creating a material uncertainty about going concern. The March 17, 2025 amendment shifts almost full financial responsibility for the NANORAY‑312 Phase 3 trial to Janssen and revises certain milestone amounts, adjusting total deal value to about $2.6 billion with royalties in the low‑teens to low‑20s percentages.